Fate Therapeutics has appointed Bob Valamehr to succeed Scott Wolchko as chief executive, effective a Jan. 1. The clinical-stage biopharmaceutical company on Friday said that Valamehr has headed the ...
Some results have been hidden because they may be inaccessible to you